NDLI: NT-29UPREGULATION OF BETA-CATENIN IN PATIENT-DERIVED GLIOBLASTOMA XENOGRAFTS EXPRESSING EGFRvIII

Content Provider	PubMed Central
Author	Roberts, Callie Chagoya, Gustavo Nanni, Cory Madan, Kwatra
Copyright Year	2014
Abstract	Amplification of the EGFR gene and subsequent overexpression of EGFR is seen in about 40% of glioblastomas. Over 50% of these glioblastomas with overexpressed EGFR also contain a variant of EGFR, known as EGFRvIII, which lacks amino acids 30-297 in its extracellular domain. Key features of EGFRvIII include a lack of binding to EGF and constitutive tyrosine kinase activity. Because EGFRvIII occurs in more than 20% of glioblastoma patients and is not present in normal brain cells, extensive efforts are being made to understand how EGFRvIII functions. Toward this goal, we recently characterized a panel of twenty patient-derived xenografts (PDGX) using a proteomics approach. This analysis revealed that seven out of the twenty PDGX expressed activated EGFR. Among those seven, three were EGFRvIII positive. A comparison of the proteomic profile of the four PDGX with activated EGFR that was not EGFRvIII with the proteomic profile of the three PDGX that expressed EGFRvIII revealed several differences. The most notable difference was the upregulation of beta-catenin. This discovery provides a novel target against EGFRvIII positive glioblastoma.
Related Links	http://dx.doi.org/10.1093/neuonc/nou265.27
Starting Page	164
File Format	PDF
ISSN	15228517
e-ISSN	15235866
Journal	Neuro-Oncology
Issue Number	Suppl 5
Volume Number	16
Language	English
Publisher	Oxford University Press
Publisher Date	2014-11-01
Access Restriction	Open
Rights Holder	Oxford University Press
Subject Keyword	Cancer Research Oncology Clinical Neurology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cancer Research Neurology (clinical) Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Genetically engineered T cells to target EGFRvIII expressing glioblastoma

PATIENT-DERIVED XENOGRAFTS MIRROR THE PROTEOMIC PROFILE OF HUMAN GLIOBLASTOMA: IMPLICATIONS FOR PERSONALIZED DRUG DEVELOPMENT

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma

Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts

Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy

Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies

NT-29UPREGULATION OF BETA-CATENIN IN PATIENT-DERIVED GLIOBLASTOMA XENOGRAFTS EXPRESSING EGFRvIII

Similar Documents

Genetically engineered T cells to target EGFRvIII expressing glioblastoma

PATIENT-DERIVED XENOGRAFTS MIRROR THE PROTEOMIC PROFILE OF HUMAN GLIOBLASTOMA: IMPLICATIONS FOR PERSONALIZED DRUG DEVELOPMENT

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts

Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma

Real-time evaluation of glioblastoma growth in patient-specific zebrafish xenografts

Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy

Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies

NT-29UPREGULATION OF BETA-CATENIN IN PATIENT-DERIVED GLIOBLASTOMA XENOGRAFTS EXPRESSING EGFRvIII